On June 20, 2024, Three-Leaf Biopharmaceutical Co., Ltd. completed its fifth revision and restatement of its articles of association and bylaws through a special resolution. The revision involves various aspects including company name, registered office address, company purpose, shareholders' responsibilities, share capital structure, and company registration revocation rights. The company's share capital is $200,000, divided into 2,000,000,000 shares with a par value of $0.0001 per share. In addition, the revised bylaws include specific provisions for shareholders' meetings, board of directors' operations, financial reporting, dividend distribution, and liquidation procedures. The revised articles of association and bylaws will have a significant impact on the company's governance structure and future operations.

On June 20, 2024, Three-Leaf Biopharmaceutical Co., Ltd. completed its fifth revision and restatement of its articles of association and bylaws through a special resolution. The revision involves various aspects including company name, registered office address, company purpose, shareholders' responsibilities, share capital structure, and company registration revocation rights. The company's share capital is $200,000, divided into 2,000,000,000 shares with a par value of $0.0001 per share. In addition, the revised bylaws include specific provisions for shareholders' meetings, board of directors' operations, financial reporting, dividend distribution, and liquidation procedures. The revised articles of association and bylaws will have a significant impact on the company's governance structure and future operations.